To include your compound in the COVID-19 Resource Center, submit it here.

miRagen reports Phase I data of systemic microRNA therapy in CTCL

miRagen Therapeutics Inc. (NASDAQ:MGEN) reported interim data from 23 evaluable patients with mycosis fungoides-type cutaneous T cell lymphoma (CTCL) in the second part of an open-label, U.S

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE